Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
Hodgkin's Disease
|
2018
|
NIAID
|
5R01AI114557-04
|
|
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$593,287
|
Hodgkin's Disease
|
2018
|
NCI
|
5R01CA203923-02
|
|
IRF-1: a brake to limit gammaherpesvirus infection and pathogenesis
|
TARAKANOVA, VERA
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$352,275
|
Hodgkin's Disease
|
2018
|
NCI
|
5R01CA157644-09
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$410,875
|
Hodgkin's Disease
|
2018
|
NCI
|
2P50CA107399-11A1
|
5662
|
Therapy-related leukemia following autologous transplantation for lymphoma
|
BHATIA, SMITA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$676,409
|
Hodgkin's Disease
|
2018
|
NCI
|
2P50CA107399-11A1
|
5663
|
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma
|
CHEN, ROBERT
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$336,786
|
Hodgkin's Disease
|
2018
|
NCI
|
5R01CA206019-03
|
|
Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients
|
COZEN, WENDY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$802,716
|
Hodgkin's Disease
|
2018
|
NIAID
|
5R01AI113130-03
|
|
New Therapeutics for Post-Transplant Lymphoproliferative Disorder
|
MARTINEZ, OLIVIA
|
STANFORD UNIVERSITY
|
CA
|
$398,138
|
Hodgkin's Disease
|
2018
|
NCI
|
5R01CA161026-08
|
|
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
|
SHIPP, MARGARET
|
DANA-FARBER CANCER INST
|
MA
|
$373,399
|
Hodgkin's Disease
|
2018
|
NCI
|
5K24CA184039-05
|
|
Molecularly Targeted Therapy for Lymphoma
|
GOPAL, AJAY
|
UNIVERSITY OF WASHINGTON
|
WA
|
$171,401
|
Hodgkin's Disease
|
2018
|
NCI
|
5P30CA006973-55
|
8084
|
Hematologic Malignancies and BMT Program - 02
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$55,373
|
Hodgkin's Disease
|
2018
|
NCI
|
3R01CA203923-02S1
|
|
IRF-1: a brake to limit gammaherpesvirus infection and pathogenesis
|
TARAKANOVA, VERA
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$58,868
|
Hodgkin's Disease
|
2018
|
NCI
|
5R01CA047006-31
|
|
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
|
ZHAO, BO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$532,500
|
Hodgkin's Disease
|
2018
|
NCI
|
1K08CA230319-01
|
|
Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic Malignancies
|
TAYLOR, JUSTIN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$244,470
|
Hodgkin's Disease
|
2018
|
NCI
|
1R01CA232616-01
|
|
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$381,507
|
Hodgkin's Disease
|
2018
|
NCI
|
1K08CA234232-01
|
|
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer
|
TURCOTTE, LUCIE
|
UNIVERSITY OF MINNESOTA
|
MN
|
$179,555
|
Hodgkin's Disease
|
2018
|
NCI
|
261200800001E-132-0-36
|
|
Repository Services for epidemiology studies
|
HEIMBROOK, DAVID
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
MD
|
$2,735,000
|
Hodgkin's Disease
|
2018
|
NCI
|
3P30CA006973-55S1
|
8084
|
Hematologic Malignancies and BMT Program - 02
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$2,068
|
Hodgkin's Disease
|
2018
|
NCI
|
3P30CA006973-55S2
|
8084
|
Hematologic Malignancies and BMT Program - 02
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$6,864
|
Hodgkin's Disease
|
2018
|
NCI
|
1ZIACP010131-23
|
|
Studies of Populations Exposed to Therapeutic Medical Radiation and Other Agents
|
KITAHARA, CARI
|
NIH
|
|
$4,577,741
|
Hodgkin's Disease
|
2018
|
NCI
|
1ZIABC011070-11
|
|
Hematopathology Diagnosis
|
JAFFE, ELAINE
|
NIH
|
|
$904,289
|